GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » Inventories, Raw Materials & Components

RNAZ (TransCode Therapeutics) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TransCode Therapeutics Inventories, Raw Materials & Components?

TransCode Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2024 was $0.00 Mil.


TransCode Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for TransCode Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransCode Therapeutics Inventories, Raw Materials & Components Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

TransCode Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TransCode Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


TransCode Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
6 Liberty Square, Suite 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Executives
Robert Michael Dudley director, 10 percent owner, officer: Chief Executive Officer C/O TRANSCODE THERAPEUTICS, 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Thomas A Fitzgerald director, officer: VP, Chief Financial Officer C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Anna Moore 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Zdravka Medarova 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Erik Manting director C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109